Patients with active cancer who were treated with apixaban (Eliquis) had a 70 percent reduction in stroke/systemic embolism, myocardial infraction or death versus treatment with warfarin. These results “are reassuring that patients with active cancer who are more prone to strokes can be safely treated with apixaban,” the lead study author told MedPage Today. However, further study is needed given the small number of people in this analysis.

Click here for more.